Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: medsunman who wrote (15537)	2/20/1998 5:46:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

There were many tests. For the one that showed a 72% tumor regression result, approximately 15 rats were in each of 6 treatment groups ( 3 concentrations of Targretin, 2 concentrations of Tamoxifen, and a control). The 72% at the highest Targretin concentration refers to the effect on the primary tumor. For 10, 30 and 100 mg of Targretin, the complete regression frequencies were 10%, 28%, and 72%. For 150 and 800 ug of Tamoxifen, the frequencies were 7% and 33%. For the control group the frequency was 0%. In addition to the complete regression (tumors disappeared), additional primary tumors showed a partial regression. These numbers were taken after 6 weeks of treatment. At the highest concentrations, Targretin cause complete regression of all tumors in 46% of the animals compared to 20% for Tamoxifen treated rats. Most of the rats had secondary tumors. This was not a clinical trial. All of the rats were treated by Ligand scientists. The 72.2% was a complete response. Another 16.7% showed a partial response. 11.1% of the tumors continued to progress. For Tamoxifen, the numbers (for the highest concentration) were 33.3% complete regression, 33.3% partial regression, 4.8% static, and 28.6% progressed.